Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Chemical Biology (2)
Signal Transduction and Targeted Therapy (1)
Nature Communications (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (3)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Cell biology
Chemical biology
Chemistry
Diseases
Drug discovery
Molecular biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–4 of 4 results

Advanced filters: Author: Meng-Ying Wu Clear advanced filters

Human Disabled-2 regulates thromboxane A₂ signaling for efficient hemostasis in thrombocytopenia

Human Disabled-2 (hDab2) is a key regulator of bleeding severity associated with thrombocytopenia. Here the authors show this is facilitated by the functional interplays of hDab2 with phosphatidic acid, AKT, and ADP/ATP release underlying thromboxane A2 signaling.

Hui-Ju Tsai
Ya-Fang Chang
Ching-Ping Tseng
ResearchOpen Access13 Nov 2024
Nature Communications

Volume: 15, P: 1-18
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Huijie Bian
Liang Chen
Ping Zhu
ResearchOpen Access14 Apr 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-8
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

A structure-based design allows the development of a potent PROTAC to degrade BAF ATPase subunits SMARCA2 and SMARCA4 via recruitment of E3 ubiquitin ligase VHL and induce cancer cell death.

William Farnaby
Manfred Koegl
Alessio Ciulli
Research10 Jun 2019
Nature Chemical Biology

Volume: 15, P: 672-680
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

William Farnaby
Manfred Koegl
Alessio Ciulli
Amendments and Corrections02 Jul 2019
Nature Chemical Biology

Volume: 15, P: 846